A State of the Art lecture titled “What the direct oral anticoagulants (DOACs) trials did and
didn't tell us” was presented at the International Society on Thrombosis and Haemostasis …

In the recent issue of Research and Practice in Thrombosis and Hemostasis, Corrales-
Medina et al.[1] reported on the clinical experience with direct oral anticoagulants (DOACs) …

Thrombotic events in children differ from those in adults in epidemiology, pathophysiology,
and anatomical location. However, anticoagulation in children is mostly based on evidence …

Background: A growing number of randomized clinical trials (RCTs) provide promising data
on pharmacokinetics/pharmacodynamics, efficacy and safety of DOAC in children and the …

This review is aimed at describing the unique challenges of anticoagulant prophylaxis and
treatment in children, and highlighting areas for research for improving clinical outcomes of …

Direct oral anticoagulants (DOACs) provide an attractive alternative for the management and
prevention of thrombosis in pediatric patients. With multiple ongoing and published pediatric …

Background: There are currently four direct oral anticoagulants (DOACs) approved for the
acute treatment and prevention of venous thromboembolism (VTE) in adults. Pediatric …

ABSTRACT Background Direct oral anticoagulants (DOACs) represent a cornerstone of
venous thromboembolism (VTE) treatment in adults. Recently, randomized controlled trials …

With the increasing incidence of thromboembolism in children and improvement in
management for patients with medically complex diseases, expanded availability of safe …

While the need for anticoagulation in children has increased over the last decades, dose
regimens of currently used anticoagulants, including low-molecular-weight heparin (LMWH) …